In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Anju Ghangurde

Anju Ghangurde is Executive Editor (APAC) for Scrip and Pink Sheet and has about two decades of experience in journalism including stints at India's mainstream financial dailies -The Economic Times, The Hindu Business Line and The Financial Express.  She covers a broad range of issues including competition and collaboration between generics and innovator firms, drug pricing and the evolving regulatory and legal framework in the region. She is also a recipient of the British Chevening Scholarship for Young Indian Journalists (2000-01) awarded by the Foreign & Commonwealth Office.

Latest From Anju Ghangurde

What’s Next At Dr Reddy’s: Biologics CDMO, Cell And Gene Therapy Push

Indian firms are getting their act together in areas like cell and gene therapy, with Dr Reddy’s aiming big and readying a facility alongside an alliance with a Chinese firm for a CAR-T therapy. The company is also doubling down in contract development and manufacturing, with an eye on opportunities in biologics.

Commercial India

Afrigen MD: WTO IP Waiver Important From ‘Freedom To Operate’ Standpoint

Afrigen’s MD, Petro Terblanche, discusses the operational freedom that the WTO intellectual property waiver provides for its COVID-19 vaccine being developed under the wider WHO-backed mRNA technology transfer hub initiative. The executive doesn’t anticipate big pharma pushback but says the alliance will “test the system”, though others believe the waiver in its current form doesn’t count for much.

Commercial Coronavirus COVID-19

Biocon Refutes Graft Charges After Regulatory Official Booked, Says Due Process Followed

Indian investigating agency probes alleged bribe paid to drugs regulator in a case pertaining to the approval process of Biocon Biologics’ insulin aspart. The company strongly denies the allegations, underscoring that all its product approvals are backed by science and clinical data.

Regulation India

Takeda Expands Hemophilia Play In India But Hemlibra Has Made Inroads

Takeda dips into the ex-Shire portfolio to debut Adynovate in India, where a large number of hemophilia patients remain undiagnosed. The extended half-life recombinant Factor VIII treatment, though, will need to take on competitors like Roche’s blockbuster, Hemlibra, which has seen rapid adoption in reimbursement ecosystems where it is included in the formulary

Commercial India

Sun’s Specialty Gambit Paying Off, Tildrakizumab Nears Sales Milestone

Tildrakizumab, including Ilumetri end market numbers, nears $500m sales mark, with the contribution of Sun's wider specialty business nearly doubling since fiscal 2018. The anti-IL-23p19 monoclonal antibody has seen global sales spurt 81% in fiscal 2022, while acne therapy Winlevi has been well received by dermatologists in the US.

Strategy Sales & Earnings

Pfizer Latest Foreign Firm To Axe India Field Force Jobs: Here’s The Big Picture Take

Pfizer effects hundreds of field force job cuts in India as it rewires its commercialization approach and creates new roles leveraging its ‘digital core’, but industry experts suggest there is a complex mix of other factors at play as well.

India Commercial
See All
UsernamePublicRestriction

Register